Interleukin-32 as a biomarker in rheumatic diseases: A narrative review

Interleukin-32 (IL-32) is an important cytokine involved in the innate and adaptive immune responses. The role of IL-32 has been studied in the context of various diseases. A growing body of research has investigated the role of IL-32 in rheumatic diseases including inflammatory arthritides (rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis) and connective tissue diseases (systemic lupus erythematosus, systemic sclerosis, granulomatosis and polyangiitis, and giant cell arteritis). IL-32 has been shown to play different roles according to the type of rheumatic diseases. Hence, the putative role of IL-32 as a biomarker is also different in each rheumatic disease: IL-32 could serve as a biomarker for disease activity in some diseases, whereas in other diseases it could be a biomarker for certain disease manifestations. In this narrative review, we summarize the associations between IL-32 and various rheumatic diseases and discuss the putative role of IL-32 as a biomarker in each disease.

[1]  F. Ribeiro-Dias,et al.  A Critical Overview of Interleukin 32 in Leishmaniases , 2022, Frontiers in Immunology.

[2]  Yong‐Gil Kim,et al.  A Paradoxical Effect of Interleukin-32 Isoforms on Cancer , 2022, Frontiers in Immunology.

[3]  Sang-Yeob Kim,et al.  Comparison of the Seven Interleukin-32 Isoforms’ Biological Activities: IL-32θ Possesses the Most Dominant Biological Activity , 2022, Frontiers in Immunology.

[4]  R. Inman.  Axial Spondyloarthritis: Current Advances, Future Challenges , 2021, Journal of rheumatic diseases.

[5]  R. Lahesmaa,et al.  The role of Interleukin‐32 in autoimmunity , 2020, Scandinavian journal of immunology.

[6]  C. Vizza,et al.  Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension , 2020, Arthritis Research & Therapy.

[7]  Shinichi Sato,et al.  Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study , 2019, Arthritis Research & Therapy.

[8]  Soohyun Kim,et al.  Interleukin‐32γ: Possible association with the activity and development of nephritis in patients with systemic lupus erythematosus , 2019, International journal of rheumatic diseases.

[9]  Siyoung Lee,et al.  Structural Characteristics of Seven IL-32 Variants , 2019, Immune network.

[10]  A. Ishizu,et al.  Pathogenesis and therapeutic interventions for ANCA-associated vasculitis , 2018, Nature Reviews Rheumatology.

[11]  Soohyun Kim,et al.  Role of IL-32 Gamma on Bone Metabolism in Autoimmune Arthritis , 2018, Immune network.

[12]  U. Zafar,et al.  Functional role of human interleukin-32 and nuclear transcription factor-kB in patients with psoriasis and psoriatic arthritis , 2018, International journal of health sciences.

[13]  Z. Rasheed,et al.  Elevated Gene Expression of Interleukin-32 Isoforms Alpha, Beta, Gamma, and Delta in the Peripheral Blood of Chronic Psoriatic Patients , 2018, Diseases.

[14]  C. Denton,et al.  SYSTEMIC SCLEROSIS , 2008 .

[15]  D. Yoon,et al.  Interleukin 32, inflammation and cancer , 2017, Pharmacology & therapeutics.

[16]  Beom-Jun Kim,et al.  Interleukin-32 Gamma Stimulates Bone Formation by Increasing miR-29a in Osteoblastic Cells and Prevents the Development of Osteoporosis , 2017, Scientific Reports.

[17]  Oliver Distler,et al.  Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis , 2017, Journal of scleroderma and related disorders.

[18]  D. Gladman,et al.  Psoriatic Arthritis. , 2017, The New England journal of medicine.

[19]  I. McInnes,et al.  Rheumatoid arthritis , 2016, The Lancet.

[20]  Rohit Sharma.  Revised International Chapel Hill Consensus Conference nomenclature of vasculitides , 2016, Radiopaedia.org.

[21]  N. Sheikh,et al.  IL-32: A Novel Pluripotent Inflammatory Interleukin, towards Gastric Inflammation, Gastric Cancer, and Chronic Rhino Sinusitis , 2016, Mediators of inflammation.

[22]  Bin Zhou,et al.  Association of Plasma IL-32 Levels and Gene Polymorphisms with Systemic Lupus Erythematosus in Chinese Han Population , 2016, Disease markers.

[23]  Soohyun Kim,et al.  High level of interleukin-32 gamma in the joint of ankylosing spondylitis is associated with osteoblast differentiation , 2015, Arthritis Research & Therapy.

[24]  C. Mohan,et al.  Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity? , 2015, BMJ : British Medical Journal.

[25]  N. Sheikh,et al.  A panoramic spectrum of complex interplay between the immune system and IL-32 during pathogenesis of various systemic infections and inflammation , 2015, European Journal of Medical Research.

[26]  Joong-Hoon Ahn,et al.  Interaction network mapping among IL-32 isoforms. , 2014, Biochimie.

[27]  Soohyun Kim.  Interleukin-32 in Inflammatory Autoimmune Diseases , 2014, Immune network.

[28]  H. Shoda,et al.  Three cases of lupus nephritis patients with serum interleukin-32γ detection , 2014, Lupus.

[29]  D. Isenberg,et al.  Systemic lupus erythematosus , 1956, The Lancet.

[30]  D. Ye,et al.  Serum levels of cytokines in systemic lupus erythematosus , 2014, Zeitschrift für Rheumatologie.

[31]  Min Zhang,et al.  IL-32 with potential insights into rheumatoid arthritis. , 2013, Clinical immunology.

[32]  L. Joosten,et al.  Novel insights into the biology of interleukin-32 , 2013, Cellular and Molecular Life Sciences.

[33]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[34]  Michele Bombardieri,et al.  Increased expression of interleukin-32 in the inflamed ileum of ankylosing spondylitis patients. , 2012, Rheumatology.

[35]  Soohyun Kim,et al.  Elevated interleukin-32 expression in granulomatosis with polyangiitis. , 2012, Rheumatology.

[36]  L. Joosten,et al.  Interleukin-32: a predominantly intracellular proinflammatory mediator that controls cell activation and cell death. , 2012, Cytokine.

[37]  Georg Schett,et al.  The pathogenesis of rheumatoid arthritis. , 2011, The New England journal of medicine.

[38]  A. Rizzo,et al.  Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. , 2011, Arthritis and rheumatism.

[39]  D. Cho,et al.  IL-32γ Induces the Maturation of Dendritic Cells with Th1- and Th17-Polarizing Ability through Enhanced IL-12 and IL-6 Production , 2011, The Journal of Immunology.

[40]  Soohyun Kim,et al.  Effect of interleukin-32gamma on differentiation of osteoclasts from CD14+ monocytes. , 2010, Arthritis and rheumatism.

[41]  D. Yoon,et al.  Identification of the most active interleukin‐32 isoform , 2009, Immunology.

[42]  Soohyun Kim,et al.  Tumor necrosis factor alpha-induced interleukin-32 is positively regulated via the Syk/protein kinase Cdelta/JNK pathway in rheumatoid synovial fibroblasts. , 2009, Arthritis and rheumatism.

[43]  G. Mabilleau,et al.  Interleukin-32 Promotes Osteoclast Differentiation but Not Osteoclast Activation , 2009, PloS one.

[44]  C. Dinarello,et al.  IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[45]  Y. Kochi,et al.  Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases , 2006, Arthritis research & therapy.

[46]  Do-Young Yoon,et al.  IL-32, a proinflammatory cytokine in rheumatoid arthritis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Aharon Rabinkov,et al.  Proteinase 3 is an IL-32 binding protein. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[48]  V. Devauchelle,et al.  Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. , 2005, European cytokine network.

[49]  D. Yoon,et al.  Interleukin-32: a cytokine and inducer of TNFalpha. , 2005, Immunity.

[50]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[51]  Huiling He,et al.  Identification of a novel gene expressed in activated natural killer cells and T cells. , 1992, Journal of immunology.

[52]  Leontine Cremerieux.  THREE CASES , 1909 .